首页> 外文期刊>Experimental and clinical transplantation >Low-Dose Aspirin Reduces the Rate of Renal Allograft Thrombosis in Pediatric Renal Transplant Recipients
【24h】

Low-Dose Aspirin Reduces the Rate of Renal Allograft Thrombosis in Pediatric Renal Transplant Recipients

机译:低剂量阿司匹林降低了儿科肾移植受者肾同种异体移植血栓形成的速率

获取原文
           

摘要

Objectives: Renal allograft thrombosis is an important cause of early renal allograft loss. A previous study from our unit showed thrombosis rates in patients who received heparin that were similar to those who did not receive any thromboprophylaxis. This study evaluated the impact of aspirin prophylaxis on renal allograft thrombosis rates in pediatric renal transplant recipients. Materials and Methods: We conducted a retrospective study of 456 consecutive pediatric allografts from deceased and living related donors over age 22 years in a single center. Routine perioperative heparin was introduced in 1994 and was subsequently changed to aspirin prophylaxis in 2000. Group 1 comprised 126 patients who did not receive any thromboprophylaxis, group 2 comprised 128 patients who received heparin, and group 3 comprised 202 patients who received aspirin therapy. Variables associated with increased risk of renal allograft loss were examined using multivariable logistic regression. Results: Thrombosis occurred in 11% (14/126) of grafts in group 1, 9% (11/128) of grafts in group 2, and 1% (2/202) of grafts in group 3 (odds ratio for aspirin group = 0.38, 95% confidence interval, 0.22-0.64; P = .02). In patients who received aspirin (group 3), there was only one renal allograft loss secondary to hemorrhage, and no grafts were lost in patients younger than 5 years of age. Conclusions: After our center introduced a change from heparin to aspirin prophylaxis, the thrombosis rate in pediatric renal allografts fell from 9% to 1%. Although there are a number of possible confounding variables, the introduction of aspirin has led to a reduced rate of renal allograft thrombosis.
机译:目的:肾同种异体移植血栓形成是早期肾同种异体移植损失的重要原因。我们的单位的先前研究表明,接受肝素的患者的血栓形成率与那些没有接受任何没有接受任何血栓造黄油的患者。该研究评估了阿司匹林预防对儿科肾移植受者肾同种异体移植血栓形成率的影响。材料和方法:我们在单一中心22岁以上的死者和生活相关捐助者的456名连续儿科同种异体移植物进行了回顾性研究。常规围手术期肝素于1994年引入,随后于2000年改变为阿司匹林预防。第1组由126名未接受任何血栓丙糖抑制的患者组成,第2组包含128名接受肝素的患者,第3组患者组成了202名接受阿司匹林治疗的患者。使用多变量逻辑回归检查与肾同种异体移植损失增加的变量。结果:血栓形成发生在11%(14/126)的血液中11%(14/126)群,9%(11/128)族的第2组接枝,第3组接枝的1%(2/202)(阿司匹林基团的差距= 0.38,95%置信区间,0.22-0.64; p = .02)。在接受阿司匹林(第3组)的患者中,只有一个肾同种异体移植物丢失,患有过度的肾移植物,并且在5岁以下的患者中没有丢失移植物。结论:在我们的中心引入了从肝素到阿司匹林预防的变化后,小儿肾同种异体移植物的血栓形成率下降了9%至1%。虽然有许多可能的混杂变量,但阿司匹林的引入导致了肾同种异体移植血栓形成的降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号